| Name | Title | Contact Details |
|---|---|---|
James Bircher |
Chief Technical Operations Officer | Profile |
LUMICKS is the leading supplier of Dynamic Single-Molecule and Cell Avidity analysis instruments` Our instruments enable – for the first time – the analysis of complex dynamic details related to the behavior and interaction of single molecules and cells` Built upon innovative and Nobel Prize-winning technologies, such as optical tweezers (Nobel Prize for Physics 2018), and STED super-resolution (Nobel Prize for Chemistry 2014), our tools enable the understanding of life to the smallest detail` Our goal is to improve human health by unlocking the power of Dynamic Single–Molecule and Cell Avidity analysis to provide unparalleled insight into the fundamental cause of disease and potential for drug optimization` These technologies are rapidly evolving as a mainstream approach in academic and pharma research for the study of DNA-protein interactions, molecular motor activity, protein folding, and cell-cell interactions`
DEKA Research and Development Corporation is a Manchester, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Avantra Biosciences FKA Decision Biomarkers, Inc. is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
INVO Bioscience is a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our INVOcell® Culture Device is a patented medical device used in the treatment of infertility that enables egg fertilization and early embryo development to take place in the woman`s body, in vivo. This revolutionary device promotes in vivo conception. It is an FDA cleared Intravaginal Culture (IVC) device that is a safe, effective and economical fertility treatment.
Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company`s founding team has decoded previously unrecognized genetic susceptibilities within general cardiovascular populations. Corvidia`s pipeline programs precisely identify patients with unique sensitivity to specific biologic pathways, potentially allowing for the rapid development of therapies targeting those pathways. This approach confers unique concepts within the field of cardiovascular medicines and an unprecedented accelerated path-to-market. Corvidia brings together a team of distinguished scientists, experienced drug developers as the management team, and a successful group of investors. Corvidia is headquartered in the Greater Boston area.